ǰÑÔ
¸ÉÑÛ²¡£¬ÓÖÃû¸ÉÔïÐԽǽáĤ²¡£¬ÊÇÑÛ¿Æ×î³£¼ûµÄ¼²²¡Ö®Ò»£¬¿ÉÒýÆðÑÛ±íËðÉ˺ÍÊÓÁ¦Ä£ºýµÈ£¬¶øÓ°Ïìµ½»¼ÕßµÄÉúÑÄÖÊÁ¿¡£ÏÖÔÚ£¬´ó´ó¶¼¸ÉÑÛ²¡»¼Õß²¡Òò²»Ã÷£¬µ«½ÏÑÏÖØµÄ¸ÉÑÛ²¡¶àÓë×ÔÉíÃâÒßÏà¹Ø¡£¶¯ÎïʵÑéÊÇÑо¿Æä·¢²¡»úÖÆµÄÖ÷ÒªÊֶΣ¬ÒÔÍùµÄ¸ÉÑÛ²¡Ä£×ÓÖ÷ÒªÓÐÕª³ýÀáÏÙ¡¢È¥³ýÑÛ±íµÄÉñ¾Ö§Åä¡¢µ÷Àí¶¯ÎïÐÔ¼¤ËØÉøÍ¸µÈ¡£ÓÉÓÚ½üÄêÀ´µÄÑо¿Ð§¹ûÏÔʾÃâÒ߸ıäÔÚ¸ÉÑ۵ķ¢²¡ÖÐÆðÖ÷Òª×÷Óã¬ÏÖÔÚ½¨ÉèµÄ¸ÉÑÛÄ£×Ó¶àΪÓÕµ¼ÑÛ±í»òÀáÏÙ±¬·¢Ñ×Ö¢·´Ó¦µÄ×ÔÉíÃâÒßÏà¹ØÄ£×Ó¡£ÒÔÏÂÖ÷ÒªÏÈÈÝÒ»ÖÖ»ùÒòÇóýСÊóÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
´ó×ÚʵÑéЧ¹ûÏÔʾ¸ÉÑÛ²¡ÊÇÒ»ÖÖÑ×Ö¢ÐÔ×ÔÉíÃâÒßÐÔ¼²²¡£¬ÌåÏÖΪÑÛ±í×ÔÉíÃâÒßÐÔTϸ°ûµÄ½þÈó£¬ÀáÏÙ¹¦Ð§µ¥Î»µÄºã¾ÃÂýÐÔÑ×Ö¢£¬¿Éµ¼Ö½ÇĤÆÁÕϹ¦Ð§µÄËðʧ¡¢ÑÛ±íÉÏÆ¤Ï¸°ûµÄµòÍö¡¢±×´Ï¸°ûµÄËðʧ¼°ÑÛ±íµÄÁÛ×´»¯Éú¡£
MRL/lprСÊó£¬ÓÉÃÀ¹úJacksonʵÑéÊÒµÄMurphyºÍRothsÔÚ1978ÄêÅàÓýÀֳɣ¬ÓÉLG/J¡¢AKR/J¡¢C3H/D ¼°C57BL/6¼¸ÖÖ²î±ðƷϵСÊó¾ÓÉһϵÁÐÖØ´óµÄÔÓ½»ÖÁµÚ12´úʱ±¬·¢£¬Æä·´×ª×ù×Ó²åÈëFas»ùÒòÄÚº¬×Ó£¬µ¼ÖÂFasת¼±í´ïÒì³£¶ø²»¿ÉÓÕµ¼µòÍö£¬´Ó¶øÊ¹ÁܰÍϸ°ûÔöֳʧ¿Ø£¬TÁܰÍϸ°ûÔöÉú¡£
¡¾Ä£×ÓÌØµã¡¿£º
MRL/lprСÊóÀáÏÙÑ×Ö¢ÔÚÊóÁä1¸öÔÂʱ±¬·¢£¬MRL/£«Ð¡ÊóÀáÏÙÑ×ÐÔ½þÈ󱬷¢½ÏÍí£¬Ò²Ã»ÓÐMRL/lprСÊóÌåÏÖµÃÑÏÖØ£¬µ«ËüÔÚÊóÁä3¸öÔÂʱҲ»á±¬·¢ÀáÏÙÑ×Ö¢£¬Õâ¾ÍÅú×¢£¬lprµÄ±äÒìÖ»ÊǼӾçÁ˸ÉÑ۵ı¬·¢£¬¶ø²»ÊÇÆäÐγɵÄÔµ¹ÊÔÓÉ¡£MRL/lprСÊóȱÏÝÐÔÁܰÍϸ°ûµÄµòÍöÊÇÓɳ£È¾É«ÌåÒþÐÔ»ùÒòlprµÄ±äÒìÒýÆðµÄ£¬Ëüµ¼ÖÂÁ˳ýÀáÏÙÍâÈ«Éí±¬·¢Fas¿¹Ô£¬Òò´Ë¿ÉÒԵóö½áÂÛ£¬lpr»ùÒòµÄ±äÒì²¢²»Êǵ¼ÖÂÀáÏÙ΢ÇéÐθıäµÄΨһÒòËØ¡£lpr»ùÒòµÄ±äÒì²¢²»¿ÉÒýÆðÑÏÖØµÄ×ÔÉíÃâÒßÐԵIJ¡±ä£¬ÓÉÓÚÐÛÐÔC3H/lprСÊóºÍϵͳÐÔÁܰÍϸ°ûÔöÉúÐÔ¼²²¡(generalized lymphoproliferative disease)СÊóµÄÀáÏÙÖв¢Î´·¢Ã÷ÁܰÍϸ°û±äÒì¡£ÕâЩ·¢Ã÷ËÆºõÖ§³ÖÕâÑùÒ»ÖÖ¼Ù˵£¬Fas¿¹ÔºÍFas¿¹Ìå²¢²»ÊÇÀáÏÙÃâÒßË𺦵ÄÒªº¦ÒòËØ¡£ÕâÖÖÄ£×ÓµÄÃâÒß²¡Àí»úÖÆÊÇÆæÒìµÄ£¬Ö÷ÒªÊÇÀáÏÙ×éÖ¯ÖÐIL-4ÓëB7-2±¬·¢µÄTh2Ðͳ¬Ãô·´Ó¦¡£
¡¾Ä£×ÓȪԴ¡¿£º
ÃÀ¹úJacksonʵÑéÊÒ(http://www.?jax:.org/index.htrnl)ºÍÄϾ©´óѧģʽ¶¯ÎïÑо¿Ëù(http:// www.nrcmm.cn)¾ù¿ÉÌṩ¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
MRL+ºÍMRL/lprСÊó³£±»ÓÃ×öϵͳÐÔºì°ßÀÇ´¯µÄÑо¿£¬ÒàÓÐÑо¿·¢Ã÷MRl/£«ºÍMRL/lpСÊó¿ÉÉú³¤ÎªÀáÏÙÑס¢ÏÑÏÙÑס¢ÈùÏÙÑ×¼°ÉàÏÂÏÙÑ×£¬ÆäÀáÏÙÒÔCD4+?ÁܰÍϸ°û½þÈóΪÖ÷ÒªÌØÕ÷£¬´ÆÐÔÌåÏֵĸüΪÑÏÖØ¡£MRL/£«ºÍMRL/lprСÊóÒ»Ö±ÊÇÍâÑó³£ÓõÄÍÙÒºÏÙºÍÀáÏÙËðÉ˵Ä×ÔÉíÃâÒßÐÔ¼²²¡Ä£×ÓÖ®Ò»¡£
?
²Î¿¼ÎÄÏ×£º
1.ÇñÅàèª.?½ÇĤÐÂÉúѪ¹ÜµÄ¶¯ÎïÄ£×Ó£®ÍâÑóҽѧ£ºÑÛ¿ÆÑ§·Ö²á£¬2000, 24 (6):360-363
2.ºú¶«¶«£¬Íõ¼ÎÈÝ£¬ÑîÔÚ¸»£®¼¤¹âÑÛËðÉ˶¯ÎïУÐÍÑо¿Ï£Íû£®¾üÊÂҽѧ¿ÆÑ§ÔºÔº¿¯£¬2010,5:489-491
3.Äô°®ÇÛ£¬Ï¯Ã磬ϯÐË»ª£¬µÈ´¿´â°ÌÕ¶¾ÐÔ½ÇĤÑ×¢òÊóÄ£×ӵĽ¨Éè¼°ÅжϹú¼ÊÑÛ¿ÆÔÓÖ¾£¬2012,12(11): 2059-2061
4.ÐìÑÒ±äÓ¦ÐÔ½áĤÑ×¶¯ÎïÄ£×ÓÑÛ¿ÆÑо¿£¬2001, 19(2):181-183
5.κÈ𻪣¬ºÂÓÀÄÈ£¬ÕÔÉÙÕ꣮×ÔÉíÃâÒßÏà¹ØÐÔ¸ÉÑÛ¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû£®ÑÛ¿ÆÐÂÏ£Íû£¬2012, 32 (7):690-693
6.Calonge MC, Pastor JC, Herreras JM, el al. Pharmacologic modulation of vascular permeability in ocular allergy in?the rat.?Invest Ophthalmol Vis Sci, 1990, 31 (1): 176-180
7.Marquart ME.Animal models of bacterial keratitis.J Biomed Biotechnol,2011,2011:680642
8.Pavan-Langston D. Herpes simplex virus ocular infections:current concepts of acute, latent and reactivated disease. Trans Am Ophthalmol Soc, 1990,88:727-796
?